Headquartered in Durham, NC Fiscal year ends December NASDAQ: FTRE fortrea.com
Fortrea (Nasdaq: FTRE) is a global contract research organization (CRO) providing clinical development solutions to the life sciences industry. The company partners with emerging and large biopharmaceutical, biotechnology, medical device, and diagnostic companies to drive healthcare innovation. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, and consulting services across more than 20 therapeutic areas. The company operates in approximately 100 countries and leverages three decades of experience along with a strong investigator site network. Fortrea was spun off from Labcorp as a standalone public company and continues to build independent operational capabilities while managing transition services agreements with its former parent. Updated
Fortrea reports at 6:30 AM ET with two straight EPS beats behind it, but only 2 of the last 4 quarters cleared the bar. Consensus sits at $0.22 per share on $671.5 million in revenue, the number that decides whether the CRO recovery is real.
Enigmatic investing legend Seth Klarman runs the Boston-based Baupost Group hedge fund that has around $27 billion in assets under management. The billionaire is a value investor in the vein of Benjamin…
Fortrea (Nasdaq: FTRE) is a global contract research organization (CRO) providing clinical development solutions to the life sciences industry. The company partners with emerging and large biopharmaceutical, biotechnology, medical device, and diagnostic companies to drive healthcare innovation.
The Wall Street consensus 12-month price target for FTRE is $21.71.
